KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Inventory: 2009-2025

Historic Change in Inventory for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $26.3 million.

  • Biomarin Pharmaceutical's Change in Inventory rose 245.09% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.1 million, marking a year-over-year increase of 50.58%. This contributed to the annual value of $63.5 million for FY2024, which is 59.55% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Change in Inventory stood at $26.3 million for Q3 2025, which was down 45.28% from $48.1 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Change in Inventory high stood at $59.1 million for Q4 2023, and its period low was -$18.1 million during Q3 2024.
  • Moreover, its 3-year median value for Change in Inventory was $30.6 million (2024), whereas its average is $29.0 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Change in Inventory plummeted by 150.03% in 2021, and later soared by 1,557.98% in 2023.
  • Biomarin Pharmaceutical's Change in Inventory (Quarterly) stood at $15.9 million in 2021, then surged by 156.32% to $40.8 million in 2022, then soared by 44.72% to $59.1 million in 2023, then slumped by 42.02% to $34.3 million in 2024, then soared by 245.09% to $26.3 million in 2025.
  • Its Change in Inventory stands at $26.3 million for Q3 2025, versus $48.1 million for Q2 2025 and $24.3 million for Q1 2025.